A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
Monica Archibald,1 Tara Pritchard,1 Hayley Nehoff,1 Rhonda J Rosengren,1 Khaled Greish,1,2 Sebastien Taurin1 1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; 2Aljawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain Abstract...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-01-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-combination-of-sorafenib-and-nilotinib-reduces-the-growth-of-castrat-peer-reviewed-article-IJN |
| _version_ | 1818845499933851648 |
|---|---|
| author | Archibald M Pritchard T Nehoff H Rosengren RJ Greish K Taurin S |
| author_facet | Archibald M Pritchard T Nehoff H Rosengren RJ Greish K Taurin S |
| author_sort | Archibald M |
| collection | DOAJ |
| description | Monica Archibald,1 Tara Pritchard,1 Hayley Nehoff,1 Rhonda J Rosengren,1 Khaled Greish,1,2 Sebastien Taurin1 1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; 2Aljawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain Abstract: Castrate-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Several tyrosine kinases have been implicated in the development and growth of CRPC, as such targeting these kinases may offer an alternative therapeutic strategy. We established the combination of two tyrosine kinase inhibitors (TKIs), sorafenib and nilotinib, as the most cytotoxic. In addtion, to improve their bioavailability and reduce their metabolism, we encapsulated sorafenib and nilotinib into styrene-co-maleic acid micelles. The micelles’ charge, size, and release rate were characterized. We assessed the effect of the combination on the cytotoxicity, cell cycle, apoptosis, protein expression, tumor spheroid integrity, migration, and invasion. The micelles exhibited a mean diameter of 100 nm, a neutral charge, and appeared highly stable. The micellar TKIs promoted greater cytotoxicity, decreased cell proliferation, and increased apoptosis relative to the free TKIs. In addition, the combination reduced the expression and activity of several tyrosine kinases and reduced tumor spheroid integrity and metastatic potential of CRPC cell lines more efficiently than the single treatments. The combination increased the therapeutic potential and demonstrated the relevance of a targeted combination therapy for the treatment of CRPC. In addition, the efficacy of the encapsulated drugs provides the basis for an in vivo preclinical testing. Keywords: sorafenib, nilotinib, castrate-resistant prostate cancer, tyrosine kinase inhibitors, nanomedicine |
| first_indexed | 2024-12-19T05:30:38Z |
| format | Article |
| id | doaj.art-59e61614d14143069f88a7a245383ea5 |
| institution | Directory Open Access Journal |
| issn | 1178-2013 |
| language | English |
| last_indexed | 2024-12-19T05:30:38Z |
| publishDate | 2016-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj.art-59e61614d14143069f88a7a245383ea52022-12-21T20:34:15ZengDove Medical PressInternational Journal of Nanomedicine1178-20132016-01-012016Issue 117920125170A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancerArchibald MPritchard TNehoff HRosengren RJGreish KTaurin SMonica Archibald,1 Tara Pritchard,1 Hayley Nehoff,1 Rhonda J Rosengren,1 Khaled Greish,1,2 Sebastien Taurin1 1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; 2Aljawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain Abstract: Castrate-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Several tyrosine kinases have been implicated in the development and growth of CRPC, as such targeting these kinases may offer an alternative therapeutic strategy. We established the combination of two tyrosine kinase inhibitors (TKIs), sorafenib and nilotinib, as the most cytotoxic. In addtion, to improve their bioavailability and reduce their metabolism, we encapsulated sorafenib and nilotinib into styrene-co-maleic acid micelles. The micelles’ charge, size, and release rate were characterized. We assessed the effect of the combination on the cytotoxicity, cell cycle, apoptosis, protein expression, tumor spheroid integrity, migration, and invasion. The micelles exhibited a mean diameter of 100 nm, a neutral charge, and appeared highly stable. The micellar TKIs promoted greater cytotoxicity, decreased cell proliferation, and increased apoptosis relative to the free TKIs. In addition, the combination reduced the expression and activity of several tyrosine kinases and reduced tumor spheroid integrity and metastatic potential of CRPC cell lines more efficiently than the single treatments. The combination increased the therapeutic potential and demonstrated the relevance of a targeted combination therapy for the treatment of CRPC. In addition, the efficacy of the encapsulated drugs provides the basis for an in vivo preclinical testing. Keywords: sorafenib, nilotinib, castrate-resistant prostate cancer, tyrosine kinase inhibitors, nanomedicinehttps://www.dovepress.com/a-combination-of-sorafenib-and-nilotinib-reduces-the-growth-of-castrat-peer-reviewed-article-IJNsorafenibnilotinibcastrate-resistant prostate cancertyrosine kinase inhibitorsnanomedicine |
| spellingShingle | Archibald M Pritchard T Nehoff H Rosengren RJ Greish K Taurin S A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer International Journal of Nanomedicine sorafenib nilotinib castrate-resistant prostate cancer tyrosine kinase inhibitors nanomedicine |
| title | A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer |
| title_full | A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer |
| title_fullStr | A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer |
| title_full_unstemmed | A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer |
| title_short | A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer |
| title_sort | combination of sorafenib and nilotinib reduces the growth of castrate resistant prostate cancer |
| topic | sorafenib nilotinib castrate-resistant prostate cancer tyrosine kinase inhibitors nanomedicine |
| url | https://www.dovepress.com/a-combination-of-sorafenib-and-nilotinib-reduces-the-growth-of-castrat-peer-reviewed-article-IJN |
| work_keys_str_mv | AT archibaldm acombinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT pritchardt acombinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT nehoffh acombinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT rosengrenrj acombinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT greishk acombinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT taurins acombinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT archibaldm combinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT pritchardt combinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT nehoffh combinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT rosengrenrj combinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT greishk combinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer AT taurins combinationofsorafenibandnilotinibreducesthegrowthofcastrateresistantprostatecancer |